文献速递肝病消化道肿瘤与早癌

射频消融对比手术治疗血管旁肝细胞癌:倾向性评分分析长期结局

Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes.
PubMed 文献 · J Hepatol · 2018-03-08

这项回顾性研究纳入2006年1月至2010年12月共283例小血管旁肝细胞癌(≤3 cm,巴塞罗那临床肝癌分期0或A期)患者,其中手术切除182例、射频消融101例,经倾向性评分匹配后各62对进行比较。中位随访7.8年,手术切除组的无进展生存率和总生存率均优于射频消融组,尤其在门静脉旁肿瘤亚组中差异显著。

要点

  • 手术切除组5年和10年无进展生存率分别为58.0%和17.8%,射频消融组分别为25.4%和14.1%(p <0.001)。
  • 手术切除组5年和10年总生存率分别为93.5%和91.9%,射频消融组分别为82.3%和74.1%(p <0.001)。
  • 门静脉旁肿瘤患者中,不同治疗方式的肝外复发和总生存差异显著(p = 0.004和p <0.001)。

核心结论

  • 对于小血管旁肝细胞癌患者,手术切除比射频消融提供更好的长期肿瘤控制和总生存,尤其是门静脉旁肿瘤。

研究设计与样本

  • 回顾性研究,经机构审查委员会批准并豁免知情同意,纳入2006年1月至2010年12月连续283例小血管旁肝细胞癌(≤3 cm,巴塞罗那临床肝癌分期0或A期)患者,接受手术切除(n = 182)或射频消融(n = 101)作为一线治疗,采用倾向性评分匹配比较结局。

主要发现

  • 中位随访7.8年,匹配后各62对患者;手术切除组5年和10年无进展生存率分别为58.0%和17.8%,射频消融组分别为25.4%和14.1%(p <0.001)。
  • 手术切除组5年和10年总生存率分别为93.5%和91.9%,射频消融组分别为82.3%和74.1%(p <0.001)。
  • 亚组分析显示,门静脉旁肿瘤患者中不同治疗方式的肝外复发和总生存差异显著(p = 0.004和p <0.001),而静脉旁肿瘤患者中无此差异。

关键数值与推荐

  • 原文未报告

临床怎么用

  • 作者认为,在选择手术切除或射频消融治疗小肝细胞癌时,需考虑肿瘤位置和瘤周肝血管类型。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The therapeutic outcomes of surgical resection (SR) or radiofrequency ablation (RFA) for perivascular hepatocellular carcinoma (HCC) have not been compared. The aim of this study was to compare SR with RFA as first-line treatment in patients with perivascular HCC and to evaluate the long-term outcomes of both therapies. METHODS: This retrospective study was approved by the institutional review board. The requirement for informed consent was waived. Between January 2006 and December 2010, a total of 283 consecutive patients with small perivascular HCCs (≤3 cm, Barcelona Clinic Liver Cancer stage 0 or A) underwent SR (n = 182) or RFA (n = 101) as a first-line treatment. The progression-free survival (PFS) and overall survival (OS) rates were compared by propensity score matching. Subgroup analysis of these outcomes was conducted according to the type of hepatic vessels. RESULTS: The median follow-up was 7.8 years. Matching yielded 62 pairs of patients. In the two matched groups, the PFS rates at 5 and 10 years were 58.0% and 17.8%, respectively, in the SR group, and 25.4% and 14.1%, respectively, in the RFA group (p <0.001). The corresponding OS rates at 5 and 10 years were 93.5% and 91.9% in the SR group and 82.3% and 74.1% in the RFA group, respectively (p <0.001). In contrast to those in patients with perivenous HCCs, subgroup analysis indicated that extrahepatic recurrence and OS were significantly different according to the treatment modality in patients with periportal HCCs (p = 0.004 and p <0.001, respectively). CONCLUSIONS: In patients with small perivascular HCCs, SR provided better long-term tumor control and OS than RFA, particularly for periportal tumors. LAY SUMMARY: Surgical resection and radiofrequency ablation are both treatment options for perivascular hepatocellular carcinoma. We compared outcomes in patients treated with either method. Surgical resection provided better long-term tumor control and overall survival than radiofrequency ablation for patients with a small perivascular hepatocellular carcinoma (≤3 cm) as a first-line treatment, particularly for periportal tumors. The location of the tumor and the type of peritumoral hepatic vessels need to be considered when choosing between surgical resection and radiofrequency ablation for small HCCs.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lee S, Kang TW, Cha DI, et al. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes. J Hepatol. 2018. PMID: 29524532. doi:10.1016/j.jhep.2018.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。